The University of Southampton
University of Southampton Institutional Repository

QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates

QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates
QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates

BACKGROUND: This qualitative sub-study aimed to explore the experiences of participants on the National Cancer Research Institute ZICE clinical trial, a randomised trial assessing two types of bisphosphonate treatment in breast cancer patients with bone metastases. Participants in the clinical trial were randomly allocated to receive either zoledronate, delivered by an intravenous (IV) infusion at clinic, or oral ibandronate, taken at home.

METHODS: Qualitative research interviews were conducted with participant groups organised by treatment and location. Interviews covered experiences and understanding of bisphosphonate treatment, the experience of the delivery mechanisms (IV or oral), side effects and benefits, and quality of life issues. The analytic framework was interpretative phenomenological analysis.

RESULTS: This paper reports on one of four superordinate themes: participants' experience of the ZICE trial, which explores the participants' experiences with clinical trial-related processes. Results show that participants were generally satisfied with their randomised treatment, although most participants had an initial preference for oral bisphosphonates. Some difficulties were reported from participants for both interventions: needle phobia, poor veins, difficulty with swallowing and gastric side effects, but pain control was improved with both modes of delivery. However, the infused bisphosphonate was reported to lose effectiveness after three weeks for some participants, whereas the oral bisphosphonate was reported to give consistent pain control. Geographical location and distance to travel made little difference to convenience of access to clinic as the reported lengths of travel time were similar due to traffic congestion in the urban areas. Most participants understood the trial processes, such as randomisation, and information about bisphosphonates but some participants showed little understanding of certain aspects of the trial. Some participants reported difficulties in accessing dental treatment due to their dentist's perceptions of bisphosphonate treatment.

CONCLUSIONS: In trials of medicinal products, especially when testing for non-inferiority, participants' preferences and idiosyncrasies in relation to treatments should not be assumed. This study has shown that in a trial context, participants' views can usefully add to the main trial outcomes and they should be taken into account when prescribing in the real world.

TRIAL REGISTRATION: ISRCTN13914201. Main ZICE MREC: 05/MRE09/57. CRUK E/04/022.

Administration, Oral, Bone Density Conservation Agents, Bone Neoplasms, Breast Neoplasms, Comprehension, Diphosphonates, England, Female, Health Knowledge, Attitudes, Practice, Health Services Accessibility, Humans, Imidazoles, Infusions, Intravenous, Pain Measurement, Patient Preference, Patient Satisfaction, Patients, Qualitative Research, Quality of Life, Time Factors, Treatment Outcome, Wales, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
1745-6215
Nelson, Annmarie
9be17968-fda0-4bd8-94cd-96d772f5083c
Fenlon, Debbie
113105c7-14ee-415b-bcc7-da38ed38655e
Morris, Jenny
1c34d387-b40d-4e9e-a008-78ec4fa681d0
Sampson, Cathy
f4e9783b-358f-44aa-ac8a-d77093bfd334
Harrop, Emily
01114a0a-f1c8-4d71-aaff-c50365561ddd
Murray, Nick
0ab49492-4445-442a-a542-1d8d937a7fc2
Wheatley, Duncan
47aa2d8c-b9cd-48fe-9933-31df68995f2e
Hood, Kerenza
62906d76-4931-4b12-9a64-0c867c7b84c1
Griffiths, Gareth
7fd300c0-d279-4ff6-842d-aa1f2b9b864d
Barrett-Lee, Peter
8e45a801-45ac-4a83-b829-9d4b7ac3d075
Nelson, Annmarie
9be17968-fda0-4bd8-94cd-96d772f5083c
Fenlon, Debbie
113105c7-14ee-415b-bcc7-da38ed38655e
Morris, Jenny
1c34d387-b40d-4e9e-a008-78ec4fa681d0
Sampson, Cathy
f4e9783b-358f-44aa-ac8a-d77093bfd334
Harrop, Emily
01114a0a-f1c8-4d71-aaff-c50365561ddd
Murray, Nick
0ab49492-4445-442a-a542-1d8d937a7fc2
Wheatley, Duncan
47aa2d8c-b9cd-48fe-9933-31df68995f2e
Hood, Kerenza
62906d76-4931-4b12-9a64-0c867c7b84c1
Griffiths, Gareth
7fd300c0-d279-4ff6-842d-aa1f2b9b864d
Barrett-Lee, Peter
8e45a801-45ac-4a83-b829-9d4b7ac3d075

Nelson, Annmarie, Fenlon, Debbie, Morris, Jenny, Sampson, Cathy, Harrop, Emily, Murray, Nick, Wheatley, Duncan, Hood, Kerenza, Griffiths, Gareth and Barrett-Lee, Peter (2013) QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates. Trials, 14, [325]. (doi:10.1186/1745-6215-14-325).

Record type: Article

Abstract

BACKGROUND: This qualitative sub-study aimed to explore the experiences of participants on the National Cancer Research Institute ZICE clinical trial, a randomised trial assessing two types of bisphosphonate treatment in breast cancer patients with bone metastases. Participants in the clinical trial were randomly allocated to receive either zoledronate, delivered by an intravenous (IV) infusion at clinic, or oral ibandronate, taken at home.

METHODS: Qualitative research interviews were conducted with participant groups organised by treatment and location. Interviews covered experiences and understanding of bisphosphonate treatment, the experience of the delivery mechanisms (IV or oral), side effects and benefits, and quality of life issues. The analytic framework was interpretative phenomenological analysis.

RESULTS: This paper reports on one of four superordinate themes: participants' experience of the ZICE trial, which explores the participants' experiences with clinical trial-related processes. Results show that participants were generally satisfied with their randomised treatment, although most participants had an initial preference for oral bisphosphonates. Some difficulties were reported from participants for both interventions: needle phobia, poor veins, difficulty with swallowing and gastric side effects, but pain control was improved with both modes of delivery. However, the infused bisphosphonate was reported to lose effectiveness after three weeks for some participants, whereas the oral bisphosphonate was reported to give consistent pain control. Geographical location and distance to travel made little difference to convenience of access to clinic as the reported lengths of travel time were similar due to traffic congestion in the urban areas. Most participants understood the trial processes, such as randomisation, and information about bisphosphonates but some participants showed little understanding of certain aspects of the trial. Some participants reported difficulties in accessing dental treatment due to their dentist's perceptions of bisphosphonate treatment.

CONCLUSIONS: In trials of medicinal products, especially when testing for non-inferiority, participants' preferences and idiosyncrasies in relation to treatments should not be assumed. This study has shown that in a trial context, participants' views can usefully add to the main trial outcomes and they should be taken into account when prescribing in the real world.

TRIAL REGISTRATION: ISRCTN13914201. Main ZICE MREC: 05/MRE09/57. CRUK E/04/022.

This record has no associated files available for download.

More information

Accepted/In Press date: 27 September 2013
Published date: 9 October 2013
Keywords: Administration, Oral, Bone Density Conservation Agents, Bone Neoplasms, Breast Neoplasms, Comprehension, Diphosphonates, England, Female, Health Knowledge, Attitudes, Practice, Health Services Accessibility, Humans, Imidazoles, Infusions, Intravenous, Pain Measurement, Patient Preference, Patient Satisfaction, Patients, Qualitative Research, Quality of Life, Time Factors, Treatment Outcome, Wales, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Organisations: Clinical Trials Unit

Identifiers

Local EPrints ID: 406311
URI: http://eprints.soton.ac.uk/id/eprint/406311
ISSN: 1745-6215
PURE UUID: b1839545-2be5-4b13-ad97-e2ade7a6bc53
ORCID for Gareth Griffiths: ORCID iD orcid.org/0000-0002-9579-8021

Catalogue record

Date deposited: 10 Mar 2017 10:44
Last modified: 16 Mar 2024 04:19

Export record

Altmetrics

Contributors

Author: Annmarie Nelson
Author: Debbie Fenlon
Author: Jenny Morris
Author: Cathy Sampson
Author: Emily Harrop
Author: Nick Murray
Author: Duncan Wheatley
Author: Kerenza Hood
Author: Peter Barrett-Lee

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×